Dr. Reddy’s Laboratories Ltd – Consensus indicates 19.3% upside potential

Dr. Reddy’s Ltd Laboratories with ticker code (RDY) now have 3 analysts covering the stock. Analyst consensus points to a buy rating. The range between the target price high and the target price low is between 70 and 59 calculating the average target price we see 64.8. Given that the stock’s previous close was at 54.31, this indicates that there is upside potential of 19.3%. There is a 50 day moving average of 54.06 and the 200 moving average is now moving to 58.98. The company has a market cap of $8,831 million. You can visit the company’s website by visiting: https://www.drreddys.com

The potential market capitalization would be $10,536 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. This segment is also active in the organic products business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are the main ingredients of finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids according to customers’ specific requirements. The Proprietary Products segment focuses on the research, development and commercialization of differentiated formulations for the therapeutic areas of dermatology and neurology. The Others segment engages in the development of therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late-stage projects at various stages of development. Its therapeutic categories mainly include gastrointestinal, cardiovascular, antidiabetic, dermatological, oncological, respiratory, stomatological, urological and nephrological. The company has entered into a collaboration, license and option agreement with Curis to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.